Innophos Holdings (Innophos Holdings) Change In Payables And Accrued Expense : $-7.4 Mil (TTM As of Sep. 2019)

View and export this data going back to 2006. Start your Free Trial

What is Innophos Holdings Change In Payables And Accrued Expense?

Innophos Holdings's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2019 was $6.1 Mil. It means Innophos Holdings's Accounts Payable & Accrued Expense increased by $6.1 Mil from Jun. 2019 to Sep. 2019 .

Innophos Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2018 was $9.5 Mil. It means Innophos Holdings's Accounts Payable & Accrued Expense increased by $9.5 Mil from Dec. 2017 to Dec. 2018 .

Innophos Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Innophos Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innophos Holdings Change In Payables And Accrued Expense Chart

Innophos Holdings Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

14.20

-16.44

14.70

-3.50

9.47

Innophos Holdings Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.53	10.64	-20.58	-3.55	6.07

Innophos Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.4 Mil.

Innophos Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Innophos Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Innophos Holdings (Innophos Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Innophos Holdings Inc (NAS:IPHS) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

259 Prospect Plains Road, Cranbury, NJ, USA, 08512

Website

http://www.innophos.com

Innophos Holdings Inc is a holding company that manufactures and sells through its subsidiaries a variety of ingredients used in the production of food, beverages, dietary supplements, pharmaceuticals, and oral care products. Innophos ingredients are made primarily from specialty phosphates. The company organizes itself into three segments namely Food, Health and Nutrition; Industrial Specialties and Other. The Food, Health and Nutrition segment contribute the maximum revenue. The company operates in U.S., Canada, Mexico and other countries.

Executives

John M Steitz	director	ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
Kim Ann Mink	director, officer: Chairman, CEO, President	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Gary A Cappeline	director	50 E RIVERCENTER BLVD, COVINGTON KY 41012
Karen R Osar	director	C/O WESTVACO CORP, ONE HIGH RIDGE PARK, STAMFORD CT 06905
Mark Santangelo	officer: Sr. VP, Mfg, Eng & EH&S	15710 JOHN F. KENNEDY BLVD., SUITE 300 HOUSTON TX 77032
Peter T Thomas	director	1000 LAKESIDE AVENUE, CLEVELAND OH 44114
Hermanus Kieftenbeld	officer: Senior VP and CFO	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
James P. Zallie	director	5 WESTBROOK CORPORATE CENTER, WESTCHESTER IL 60154
Randy Gress	director, officer: CEO	259 PROSPECT PLAINS ROAD, P O BOX 8000, CRANBURY NJ 08512-8000
Stephen M Zide	director	BAIN CAPITAL PARTNERS, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Richard Heyse	officer: VP-Chief Financial Officer	259 PROSPECT PLAINS ROAD, BUILDING G, P O BOX 8000, CRANBURY NJ 08512-8000
Bain Capital Investors Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Vii Lp	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Llc	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Lp	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116